Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.12M$3.12Mderivedno prior Q4 2015 on file Net Income-$5.86M-$5.86MderivedN/M vs Q4 2015 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,348,000+54.9% Operating Incomederived$6,740,000N/M Operating Cash Flowderived-$990,000N/M Margins · derivedGross margin43.2%
Operating margin215.9%
Net margin-187.7%
ended Dec 31, 2016 · filed Mar 31, 2017 · 90 d after period end